Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

Summary

The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.

Timeline

Start

2005-05

Primary completion

2006-07

Completion

2006-07

Outcome

Met primary endpoint

registry NUMBER Lubiprostone: 12.1 percentage of participants NUMBER Placebo: 5.7 percentage of participants analysis (unspecified test); Lubiprostone vs Placebo; p = 0.023; NCT00399542 ↗

Drugs

Indications